Head-to-head biologic therapy in Crohn's disease

Affiliations

¹ Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford OX3 9DU, UK; Department of Gastroenterology, St Richard's and Worthing Hospitals, University Hospitals Sussex NHS Foundation Trust, West Sussex, UK.
² Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford OX3 9DU, UK. Electronic address: jack.satsangi@ndm.ox.ac.uk.

Comment

Thomas P Chapman et al. Lancet. 2022.

. 2022 Jun 11;399(10342):2169-2171.

doi: 10.1016/S0140-6736(22)00843-1.

¹ Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford OX3 9DU, UK; Department of Gastroenterology, St Richard's and Worthing Hospitals, University Hospitals Sussex NHS Foundation Trust, West Sussex, UK.
² Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford OX3 9DU, UK. Electronic address: jack.satsangi@ndm.ox.ac.uk.

No abstract available

Comment on

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.